GTBP Stock Overview
A clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
GT Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.27 |
| 52 Week High | US$10.66 |
| 52 Week Low | US$1.72 |
| Beta | 1.48 |
| 1 Month Change | 1.79% |
| 3 Month Change | 2.71% |
| 1 Year Change | -31.73% |
| 3 Year Change | -96.08% |
| 5 Year Change | -97.83% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06
GT Biopharma files for $150M mixed shelf offering
Oct 13We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21GT Biopharma GAAP EPS of -$0.10 beats by $0.07
Aug 11Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth
Nov 24Shareholder Returns
| GTBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | -9.0% | -0.3% |
| 1Y | -31.7% | -15.0% | 8.1% |
Return vs Industry: GTBP underperformed the US Biotechs industry which returned -15% over the past year.
Return vs Market: GTBP underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| GTBP volatility | |
|---|---|
| GTBP Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: GTBP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GTBP's weekly volatility has decreased from 26% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 1 | Michael Breen | www.gtbiopharma.com |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. Fundamentals Summary
| GTBP fundamental statistics | |
|---|---|
| Market cap | US$5.76m |
| Earnings (TTM) | -US$13.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs GTBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.16m |
| Earnings | -US$13.16m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GTBP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 07:00 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GT Biopharma, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Charles Butler | Roth Capital Partners |
| Jonathan Aschoff | Roth Capital Partners |